Skip to Content
MilliporeSigma
All Photos(1)

Documents

PHR1438

Supelco

Simvastatin

Pharmaceutical Secondary Standard; Certified Reference Material

Synonym(s):

Simvastatin

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C25H38O5
CAS Number:
79902-63-9
Molecular Weight:
418.57
MDL number:
MFCD00072007
UNSPSC Code:
41116107
PubChem Substance ID:
329822601
NACRES:
NA.24

grade

certified reference material
pharmaceutical secondary standard

Quality Level

300

agency

traceable to BP 739
traceable to Ph. Eur. S0650000
traceable to USP 1612700

API family

simvastatin

CofA

current certificate can be downloaded

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

mp

127-132 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

-10 to -25°C

SMILES string

[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]3C[C@@H](O)CC(=O)O3)OC(=O)C(C)(C)CC

InChI

1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1

InChI key

RYMZZMVNJRMUDD-HGQWONQESA-N

Gene Information

human ... HMGCR(3156)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Certified pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to pharmacopeia primary standards.
Simvastatin is a hypolipidemic drug, which lowers plasma cholesterol by inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. It is widely used in the treatment of hypercholesterolemia.

Application

Simvastatin may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations by various chromatography techniques.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Biochem/physiol Actions

Simvastatin is a specific inhibitor of HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early step in cholesterol biosynthesis. It is used in the treatment of hypercholesterolemia, as it reduces levels of low-density lipoproteins and triglycerides, and raises high-density lipoprotein levels. Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding β-hydroxyacid, and can be activated prior to use with NaOH in EtOH treatment. It is a synthetic analog of lovastatin (Cat. No. M2147).

Analysis Note

These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.

Other Notes

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

Footnote

To see an example of a Certificate of Analysis for this material enter LRAB3719 in the slot below. This is an example certificate only and may not be the lot that you receive.

Recommended products

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

related product

Product No.
Description
Pricing

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H361d

Hazard Classifications

Repr. 2

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
LRAD2788
LRAC5697
LRAA9215
LRAB3719
LRAA2746

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 9

1 of 9

Ezetimibe Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1866

Ezetimibe

Tenivastatin ammonium salt analytical standard

Supelco

07363

Tenivastatin ammonium salt

Mevastatin An antibiotic that acts as a potent inhibitor of HMG-CoA reductase, thus suppressing Ras farnesylation.

Sigma-Aldrich

474700

Mevastatin

Supelco

Supelco

PHR1928

Rosuvastatin Calcium

Atorvastatin Calcium Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1422

Atorvastatin Calcium

HOE 140 ≥94%

Sigma-Aldrich

H157

HOE 140

Levetiracetam Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1447

Levetiracetam

Simvastatin, Sodium Salt InSolution, ≥95%

Sigma-Aldrich

567022

Simvastatin, Sodium Salt

Oxcarbazepine Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1635

Oxcarbazepine

Simultaneous determination of ezetimibe and simvastatin in pharmaceutical formulations by dual-mode gradient LC.
Ozalt?n N & Ucakturk E
Chromatographia, 66(1), 87-91 (2007)
Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs.
Kang BK, et al.
International Journal of Pharmaceutics, 274(1-2), 65-73 (2004)
HPLC determination of ezetimibe and simvastatin in pharmaceutical formulations.
Ashfaq M, et al.
Journal of the Chilean Chemical Society, 52(3), 1220-1223 (2007)
Determination of lovastatin and simvastatin in pharmaceutical dosage forms by MEKC.
Srinivasu MK, et al.
Journal of Pharmaceutical and Biomedical Analysis, 29(4), 715-721 (2002)
A Marot et al.
Acta clinica Belgica, 66(2), 134-136 (2011-06-03)
Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy. Predisposing factors include comorbidities and the concomitant use of cytochrome P-450 (CYP) 3A4 inhibitors. We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service